

a2
Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

a3
12. (Amended) Use of a polypeptide according to claim 9 wherein a degenerative disorder is a degenerative disorder of the central nervous system.

a4
16. (Amended) Use of a polypeptide according to claim 15 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

17. (Amended) Use of a polypeptide according to claim 9 wherein the polypeptide is synthetic.

a5
20. (Amended) A method according to claim 18 wherein the animal is a mammal.

a6
22. (Amended) A method according to claim 18 wherein the neurodegenerative disorder is a degenerative disorder of the central nervous system.

a7
26. (Amended) A method according to claim 24 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

27. (Amended) A method according to claim 18 wherein the mutation results in a truncated product from the PKC γ gene being produced.

28 30. (Amended) A method according to claim 18 wherein detection of the presence of the mutation in the PKC γ gene is achieved by detecting altered levels of the mRNA transcripts or mRNA precursor.

31. (Amended) A method according to claim 18 wherein the mutation in the PKC γ gene is detected using antibodies raised to the truncated PKC type I polypeptide.

99 41. (Amended) An antibody according to claim 38 wherein the antibody is a monoclonal antibody.

910 43. (Amended) Use of an antibody according to claim 38 for the manufacture of a medicament for preventing, delaying, treating or inhibiting degeneration of the nervous system.

44. (Amended) Use of an antibody according to claim 38 in a diagnostic assay for testing an human thought to have or be predisposed to having a neural degenerative disorder.

Abstract:

211 At page 58, the page following the claims, please insert — The present invention relates to the use of a polynucleotide fragment comprising PKC γ gene including type 1 subtype of protein kinase C in the manufacture of a medicament for treating a neurodegenerative disorder. The invention further relates to use of a polypeptide which comprises protein kinase C type 1 in the manufacture of a medicament for treating a neurodegenerative disorder. Further disclosed is a method of testing an animal, such as human, thought to have or be predisposed to having a neurodegenerative disorder which comprises detecting the presence of a mutation in PKC γ gene and/or its associated promoter.